2.06  0.08 (4.04%)		10-28 16:00
Open: 2.0076 High: 2.095 Volume: 2,204,705		Pre. Close: 1.98 Low: 1.98 Market Cap: 147(M)

Short term
Mid term
Targets	6-month :	2.96	1-year :	3.37
Resists	First :	2.53	Second :	2.89
Pivot price	2.3
Supports	First :	1.96	Second :	1.63
MAs	MA(5) :	2.14	MA(20) :	2.38
	MA(100) :	3.67	MA(250) :	3.07
MACD	MACD :	-0.3	Signal :	-0.3
%K %D	K(14,3) :	6.5	D(3) :	12
RSI	RSI(14): 33.3
52-week	High :	6.94	Low :	1.21

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ZNTL ] has closed above bottom band by 16.6%. Bollinger Bands are 29.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.1 - 2.11	2.11 - 2.12
Low:	1.95 - 1.97	1.97 - 1.98
Close:	2.04 - 2.06	2.06 - 2.08

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Tue, 27 Oct 2026
BlackRock reports sole voting power over 3.80M Zentalis (ZNTL) shares in a passive stake update. - Stock Titan

Sat, 24 Oct 2026
Zentalis Pharmaceuticals, Inc. Estimates – NASDAQ:ZNTL - TradingView

Fri, 23 Oct 2026
Zentalis Pharmaceuticals (ZNTL) Reports Interim DENALI Study Res - GuruFocus

Fri, 23 Oct 2026
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026 - GlobeNewswire

Mon, 19 Oct 2026
Zentalis Pharmaceuticals (ZNTL) Shares Rise After Positive Mid-S - GuruFocus

Sun, 18 Oct 2026
Zentalis Pharmaceuticals reports 15.8‑month survival in ovarian cancer subgroup - Mugglehead Investment Magazine

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	98 (M)
Shares Float	57 (M)
Held by Insiders	21.8 (%)
Held by Institutions	50.5 (%)
Shares Short	5,960 (K)
Shares Short P.Month	4,990 (K)

EPS	-1.97
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-33.2 %
Return on Equity (ttm)	-66.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.53
Qtrly Earnings Growth	0 %
Operating Cash Flow	-128 (M)
Levered Free Cash Flow	-79 (M)

PE Ratio	-1.06
PEG Ratio	0
Price to Book value	1.02
Price to Sales	0
Price to Cash Flow	-1.58

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.